SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending following the release of pivotal Phase 3 trial data for its pancreatic cancer candidate, daraxonrasib, which significantly improved overall survival compared to standard chemotherapy. Investors and clinicians are actively discussing the transformative clinical outcomes, which have sparked heightened acquisition speculation and multiple analyst price target increases as the company advances its regulatory filings.

SharonAI Holdings, Inc. operates as a holding company that develops and delivers GPU cloud computing and AI solutions. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI is currently experiencing intense attention and high volatility driven by a massive multi-year infrastructure contract and strategic positioning from prominent institutional investors like Leopold Aschenbrenner's Situational Awareness. The community is actively debating the stock's potential for a major short squeeze due to its tight float, with many focusing on its role as a niche 'NeoCloud' provider amid broader AI hardware demand.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

The VanEck Gold Miners ETF (GDX) remains a focal point for investors as central banks aggressively expand their gold reserves to hedge against geopolitical fragmentation and sustained inflationary pressures. The community is actively debating the sector's long-term outlook, weighing the potential for a monetary reset and fiscal stimulus against short-term volatility driven by rate hike speculation and shifting dollar dynamics.

Select Sector SPDR Trust (The) - State Street Financial Select Sector SPDR ETF

Financial Select Sector SPDR Fund

The Financial Select Sector SPDR Fund (XLF) is currently trending as investors debate the potential for a rotational shift into financial stocks, driven by bullish technical breakouts and institutional accumulation. While some market participants are monitoring banking stability and credit sector risks, the community remains divided between those capitalizing on the sector's relative strength and others warning of a broader economic cooling period.

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.

Affirm Holdings Inc - Ordinary Shares - Class A

Affirm Holdings Inc

Affirm is currently trending as a focal point for fintech investors, with strong sentiment driven by its resilient recurring loan revenue and the expansion of its partnership with Google's AI-driven platforms. The community is actively debating the stock's long-term valuation versus cyclical credit risks, with many traders closely monitoring its price action for signs of a major breakout.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending due to strong institutional accumulation and positive analyst revisions, with market participants closely watching its role as critical infrastructure for scaling enterprise AI workloads. The community is actively debating the stock's growth trajectory ahead of its upcoming earnings report, focusing on how its observability platform benefits from the broader shift toward agentic AI deployment.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing renewed investor interest and upward price momentum driven by strong institutional backing, consistent GAAP profitability, and a high-volume short interest that has led to speculation about a potential short squeeze. The community is actively discussing the stock's significant undervaluation relative to its growth prospects, while monitoring institutional buying and positive analyst sentiment as key catalysts for a potential breakout.

Corning, Inc. engages in the provision of glass for notebook computers, flat panel desktop monitors, display televisions, and other information display applications, carrier network and enterprise network products for the telecommunications industry, ceramic substrates for gasoline and diesel engines in automotive and heavy-duty vehicle markets, laboratory products for the scientific community and polymer products for biotechnology applications, optical materials for the semiconductor industry and the scientific community, and polycrystalline silicon products and other technologies. It operates through the following segments: Optical Communications, Display, Specialty Materials, Automotive, and Life Sciences. The Optical Communications segment is classified into two main product groupings: carrier and enterprise network. The carrier network group consists of products and solutions for optical-based communications infrastructure for services such as video, data, and voice communications. The enterprise network group consists primarily of optical-based communication networks sold to businesses, governments, and individuals for their own use. The Display Technologies segment manufactures glass substrates for flat panel displays, including organic light-emitting diodes and liquid crystal displays that are used primarily in televisions, notebook computers, desktop monitors, tablets, and handheld devices. The Specialty Materials segment is involved in the manufacture of products that provide material formulations for glass, glass ceramics and crystals, and precision metrology instruments and software. The Automotive segment manufactures ceramic substrates and filter products for emissions control in mobile applications around the world as well as technical glass and optic products and solutions for the interior and exterior of vehicles. The Life Sciences segment develops, manufactures, and supplies laboratory products. The company was founded by Amory Houghton Sr. in 1851 and is headquartered in Corning, NY.

Corning, Inc.

Corning is trending as investors aggressively position themselves for a prolonged AI infrastructure buildout, viewing the company as a critical backbone in the fiber optic and photonics supply chain. While some traders are expressing frustration with recent volatility and high valuations, community sentiment remains heavily focused on the company's multi-billion dollar hyperscaler partnerships as a foundational catalyst for long-term growth.

Coeur Mining, Inc. engages in the well-diversified, growing precious metals producer with a focus on generating sustainable, high-quality cash flow and returns from a balanced, prospective asset base in mining-friendly jurisdictions along with commitment to exploration and expansions. It operates through the following segments: Palmarejo, Rochester, Kensington, Wharf and Silvertip. The Palmarejo segment includes a gold-silver complex. The Rochester segment operates an open pit heap leach silver-gold mine in northwestern Nevada. The Kensington segment relates to an underground gold mine located north of Juneau, Alaska. The Wharf segment focuses on an open pit heap leach gold mine located near Lead, South Dakota. The Silvertip segment silver-zinc-lead exploration located in the state of Sonora in northern Mexico. The company was founded in 1928 and is headquartered in Chicago, IL.

Coeur Mining Inc

Coeur Mining is drawing significant community focus due to record-breaking financial performance and the anticipation surrounding its strategic acquisition of New Gold, which is expected to create a diversified gold and copper powerhouse. Investors are actively discussing the firm's strengthened cash flow profile and operational leverage as catalysts for a potential re-rating in a favorable commodities market.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is experiencing heightened volatility and intense institutional interest as investors focus on the final stages of the TopBuild acquisition and its impact on the company's long-term scaling strategy. The community remains deeply divided, with many traders closely monitoring high short interest and technical setups while others emphasize their commitment to holding the stock for multi-year growth based on leadership's proven track record.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati

Ionis grants Recordati ex-U.S. rights to zilganersen for Alexander disease while retaining U.S. commercialization and securing upfront and royalty payments.

FDA Expands IONS' Tryngolza Label to Treat Severe Hypertriglyceridemia

Ionis wins FDA approval to expand Tryngolza to severe hypertriglyceridemia, opening a broader market as the first approved treatment for the condition. 

IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval

Equity

Goldman Sachs upped its price target on Ionis to $75 and maintained a ‘Neutral’ rating on the shares. 


TRYNGOLZA (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA (olezarsen) as an adjunct to diet to reduce triglycerides (TG) and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: TG greater than or...

Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Ludwig Hantson, Ph.D., an accomplished global biopharmaceutical leader, to the Ionis Board of Directors, effective immediately.We are pleased to welcome Dr. Hantson to the board, said Joseph Loscalzo, M.D., Ph.D...

BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag

Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.

Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data analyses from the landmark Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG) will be presented during four oral presentations at upcoming medical conferences. Data will be presented...

Why Is Ionis Pharmaceuticals (IONS) Up 3.4% Since Last Earnings Report?

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). Results from the two Phase 3 trials, B-Well 1 and B-Well 2, were simultaneously published...

BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal

Biogen advances Alzheimer's drug diranersen to late-stage trials after a phase II study misses its main goal but shows cognitive and biomarker gains.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Ionis Pharmaceuticals Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

IONSIonis Pharmaceuticals Inc

Fundamentals

Latest IONS News